Author

P. Gallipoli

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 3 Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:gene regulatory network inference· 2 Organism:human· 2 Organism:mouse· 2 Approach:statistical model· 2 Research Focus:cell type annotation· 1

Frequent Co-Authors

G. Giotopoulos· 3 shared B. J. P. Huntly· 2 shared C. Philippe· 2 shared D. Sasca· 2 shared E. Meduri· 2 shared F. Basheer· 2 shared G. S. Vassiliou· 2 shared H. Yun· 2 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

G. Giotopoulos

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

SCD inhibition eradicates AML displaying high de novo fatty acid desaturation and synergizes with chemotherapy

V. Dembitz, H. Lawson, R. Burt, C. Philippe, S. C. James, S. Atkinson, J. Durko, L. M. Wang, J. Campos, A. M. Magee, K. Woodley, M. J. Austin, A. Rio-Machin, P. Casado-Izquierdo, F. Bewicke-Copley, , P. Gallipoli

SCD inhibition induces AML cell death and synergizes with chemotherapy to prolong survival in murine AML models.

bioRxiv · Aug 2, 2023Cancer Biology

Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 co-activation

V. Shah, G. Giotopoulos, H. Osaki, M. Meyerhoefer, E. Meduri, B. Schubert, H. Yun, S. J. Horton, S. Agrawal-Singh, P. S. Haehnel, F. Basheer, D. Lugo, M. W. Kuehn, B. Guezguez, M. Theobald, , D. Sasca

This study identifies p300-mediated compensatory transcriptional programs that drive acute resistance to BET inhibitors in AML and suggests sequential BET- and p300-inhibition as a therapeutic strategy.

bioRxiv · Sep 14, 2022 · PreprintCancer Biology

Mannose metabolism inhibition sensitizes acute myeloid leukemia cells to cytarabine and FLT3 inhibitor therapy by modulating fatty acid metabolism to drive ferroptotic cell death.

K. Woodley, L. S. Dillingh, G. Giotopoulos, P. Madrigal, K. M. Rattigan, C. Philippe, V. Dembitz, A. S. M. Magee, R. Asby, L. N. van de Lagemaat, C. Mappereley, S. C. James, J. H. Prehn, K. Tzelepis, K. Rouault-Pierre, , P. Gallipoli

This study shows that inhibiting mannose metabolism sensitizes AML cells to cytarabine and FLT3 inhibitors by promoting ferroptotic cell death through fatty acid metabolism changes.

bioRxiv · May 16, 2022Cancer Biology

Mutational synergy coordinately remodels chromatin accessibility, enhancer landscape and 3-Dimensional DNA topology to alter gene expression during leukemia induction

H. Yun, S. Vohra, A. Mupo, G. Giotopoulos, D. Sasca, S. J. Horton, S. Agrawal-Singh, E. Meduri, F. Basheer, L. Marando, M. Gozdecka, O. M. Dovey, A. Castillo-Venzor, X. Wang, P. Gallipoli, , B. J. P. Huntly

The paper investigates how mutations synergize to alter chromatin accessibility, enhancer landscapes, and 3D DNA topology in leukemia induction using a murine model.

bioRxiv · Mar 20, 2020Cancer Biology